Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06810778 · ClinicalTrials.gov registry record · Phase 1
Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
A Phase 1 study of T-cell-prolymphocytic Leukemia and Cutaneous T-Cell Lymphoma Refractory, sponsored by Jonsson Comprehensive Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT06810778: Recruiting Phase 1 study of T-cell-prolymphocytic Leukemia and Cutaneous T-Cell Lymphoma Refractory, sponsored by Jonsson Comprehensive Cancer Center.
NCT06810778 is a Phase 1 study of T-cell-prolymphocytic Leukemia and Cutaneous T-Cell Lymphoma Refractory that is actively recruiting participants, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 12 participants, below the 180-participant average among 7 other T-cell-prolymphocytic Leukemia trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06810778, a Phase 1 study of T-cell-prolymphocytic Leukemia and Cutaneous T-Cell Lymphoma Refractory, is actively recruiting participants, sponsored by Jonsson Comprehensive Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, phase I/II study of duvelisib in combination with Venetoclax for patients with relapsed/refractory NHL. Duvelisib is an FDA approved, marketed product used to treat certain patients with leukemia and lymphoma and Venetoclax, which is approved for treatment of certain patients with acute myeloid leukemia. The combination of these two drugs is experimental. Experimental means that it is not approved by the United States Food and Drug Administration (FDA). The researchers want to find out how safe it is to combine these drugs and how well this combination can work for your cancer.
Primary Outcome
Phase I: Will be graded according to the Common Terminology Criteria for Adverse Events version 5.0.
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG Duvelisib
Study Locations (1)
California
- David Geffen School of Medicine at the University of California at Los Angeles - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2025-05-02 |
| Est. Completion | 2031-06-01 |
| Phase | Phase 1 |
What NCT06810778 shows while recruiting
NCT06810778 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 180-participant average among 7 other T-cell-prolymphocytic Leukemia trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with T-cell-prolymphocytic Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Venetoclax is the first listed.
NCT06810778 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06810778 about?
NCT06810778 is a clinical study titled "Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)". This is an open-label, phase I/II study of duvelisib in combination with Venetoclax for patients with relapsed/refractory NHL. Duvelisib is an FDA approved, marketed product used to treat certain patients with leukemia and lymphoma and Venetoclax, which is approved for treatment of certain patients ...
What is the current status of trial NCT06810778?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2025-05-02. Estimated completion is 2031-06-01.
What conditions does trial NCT06810778 study?
This clinical trial studies the following conditions: T-cell-prolymphocytic Leukemia, Cutaneous T-Cell Lymphoma Refractory.
What interventions are being tested in trial NCT06810778?
The interventions under investigation include: Venetoclax (DRUG), Duvelisib (DRUG).
Who is sponsoring clinical trial NCT06810778?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06810778 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for T-cell-prolymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
RECRUITING · Phase 1
-
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
RECRUITING · Phase 1
-
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients
ACTIVE NOT RECRUITING · Phase 1
-
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
A Registry for People With T-cell Lymphoma
RECRUITING
-
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI